EP
REGN icon

Eudaimonia Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Eudaimonia Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20
Closed -$9K – 1135
2021
Q1 		$9K Buy
+20
New +$9.74K ﹤0.01% 1194
2020
Q2 		– Sell
-79
Closed -$39K – 752
2020
Q1 		$39K Buy
+79
New +$32.6K 0.02% 519

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Eudaimonia Partners's REGN Position: Q2 2021 in Review

Eudaimonia Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2021, closing a stake of 20 shares — an estimated $9K sold.

Eudaimonia Partners first reported a position in REGN in Q1 2020 and held it in 2 quarters. The position peaked at $39K in Q1 2020. 971 funds tracked by Wall St. Rank hold REGN as of Q2 2021.

  • Eudaimonia Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 20 Regeneron Pharmaceuticals shares in Q2 2021, an estimated $9K.
  • Eudaimonia Partners first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Eudaimonia Partners's Regeneron Pharmaceuticals position peaked at $39K in Q1 2020.
  • 971 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.